Urethral strictures following high-dose-rate brachytherapy for prostate cancer: Analysis of risk factors - Abstract

PURPOSE:High-dose-rate brachytherapy is an established technique to deliver a conformal dose of radiation to patients with prostate cancer.

The William Buckland Radiotherapy Center has been performing high-dose-rate brachytherapy with external beam radiation treatment for prostate cancer since 1998 and has an extensive prospective database on all patients treated. The purpose of this analysis was to assess the risk of stricture formation and identify the predictive or causative factors.

METHODS AND MATERIALS: Three hundred fifty-four patients were treated between 1998 and 2008. Patients received one of three differing dose schedules: 20Gy in four treatments (20Gy/4), 18Gy/3, and 19Gy/2 during three sequential time periods. Nelson-Aalen cumulative hazard modeling was used to estimate risk of events over time. Potential risk factors, including dose, were identified and used in the analysis.

RESULTS: There were 45 patients who developed at least one stricture, an overall risk of 8.2% at 2 years. The 2-year risk of stricture formation was 3.4%, 2.3%, and 31.6% for 18Gy/3, 20Gy/4, and 19Gy/2, respectively. Most strictures occurred in the bulbomembranous urethra (50%) or external sphincter region (33%). On multivariable analysis, the dose schedule used was the only significant predictor for increased stricture formation.

CONCLUSIONS: In our patients, those who received 19Gy/2 were at a significantly higher risk of stricture formation. Most of these strictures were mild, requiring only one intervention but a 2-year stricture risk of 31.6% was striking, and we have modified our protocol.

Written by:
Hindson BR, Millar JL, Matheson B. Are you the author?
William Buckland Radiation Oncology, Alfred Health, Melbourne, Victoria, Australia; Department of Surgery, Monash University, Melbourne, Victoria, Australia.

Reference: Brachytherapy. 2012 May 4. Epub ahead of print.
doi: 10.1016/j.brachy.2012.03.004

PubMed Abstract
PMID: 22561217

UroToday.com Prostate Cancer Section